Galderma will present data on Relfydess ® (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology – which further demonstrate its rapid onset and ...
Please provide your email address to receive an email when new articles are posted on . Relfydess has received a positive decision for treatment of frown lines and crow’s feet in the European Union.
This positive decision, and the previous Therapeutic Goods Administration approval in Australia, were based on results from the phase III READY (RElabotulinumtoxin Aesthetic Development StudY) ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset ...
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for ...
“With Relfydess TM, Galderma is introducing a highly differentiated and innovative neuromodulator, reinforcing our leadership and strong growth in this field, and our commitment to developing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results